June 22, 2022
Gemelli Biotech Completes $19 Million Series A Financing
Gemelli Biotech Corp. (“Gemelli”), a company focused on improving health by providing precision diagnostics for gastrointestinal (GI) diseases, today announced the completion of a $19 million Series A financing. Blue Ox Healthcare Partners (“Blue Ox”), a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, CerraCap Ventures, and several family offices.
October 27, 2020
Gemelli Biotech Launches Novel Breath Test Measuring Hydrogen, Methane and Hydrogen Sulfide
Los Angeles- and Raleigh-based Gemelli Biotech announced the launch of a novel breath test called trio-smart™ that provides a more complete fermented gas profile of a patient’s microbiome by measuring levels of hydrogen, methane, and hydrogen sulfide after the consumption of a sugar substance (lactulose or glucose). trio-smart™ is a Laboratory Developed Test (LDT) conducted at a CLIA-certified lab.
October 15, 2019
Gemelli Biotech, Innovator in Microbiome Space, Producer of ibs-smart™, Announces Scientific Advisory Board
Gemelli Biotech, producers of the ibs-smart™ blood test for irritable bowel syndrome with a diarrheal component (IBS-D and IBS-M), announced the formalization of a Scientific Advisory Board to support the company’s expansion into new markets and new offerings.
May 20, 2019
Second-Generation Blood Test for Irritable Bowel Syndrome (IBS) Validated as Providing Most Conclusive Diagnosis of Inclusion for IBS
Gemelli Biotech, in partnership with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, announced new findings that validate a second-generation diagnostic blood test for irritable bowel syndrome (IBS) as the most accurate ever.
January 9, 2019
New ELISA blood test from Gemelli Biotech offers important insights to patients with Scleroderma and Systemic Sclerosis
The new blood test, sclero-smart™, measures levels of anti-vinculin, recently found to be elevated in patients with scleroderma and associated with gastrointestinal complications. This suggests a link between scleroderma and the gut microbiome, a finding that could open the door to discoveries of new microbiome-related therapeutic and diagnostic tools for scleroderma.
October 10, 2018
Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS) announced by Gemelli Biotech™ in partnership with the Medically Associated Science and Technology Program (MAST) at Cedars-Sinai
Gemelli Biotech™, a specialty biotechnology company focused on developing novel diagnostics and therapeutics for the human microbiome, announced the commercial availability of ibs-smart™, a second-generation blood test for Irritable Bowel Syndrome (IBS). ibs-smart™ offers an advancement in the specificity and accuracy of measuring two antibodies (anti-CdtB and anti-vinculin) in diagnosing Diarrhea Predominant and Mixed-Type IBS (IBS-D and IBS-M).